JP2020531539A - カナキヌマブの使用 - Google Patents

カナキヌマブの使用 Download PDF

Info

Publication number
JP2020531539A
JP2020531539A JP2020511450A JP2020511450A JP2020531539A JP 2020531539 A JP2020531539 A JP 2020531539A JP 2020511450 A JP2020511450 A JP 2020511450A JP 2020511450 A JP2020511450 A JP 2020511450A JP 2020531539 A JP2020531539 A JP 2020531539A
Authority
JP
Japan
Prior art keywords
canakinumab
patient
hscrp
months
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020511450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531539A5 (https=
Inventor
リドカー，ポール
トゥレン，トム
ベルマン，ジョルジーナ
リビー，ピーター
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020531539A publication Critical patent/JP2020531539A/ja
Publication of JP2020531539A5 publication Critical patent/JP2020531539A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020511450A 2017-08-25 2018-08-24 カナキヌマブの使用 Withdrawn JP2020531539A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549971P 2017-08-25 2017-08-25
US62/549,971 2017-08-25
US201762584380P 2017-11-10 2017-11-10
US62/584,380 2017-11-10
PCT/IB2018/056465 WO2019038737A1 (en) 2017-08-25 2018-08-24 USE OF CANAKINUMAB

Publications (2)

Publication Number Publication Date
JP2020531539A true JP2020531539A (ja) 2020-11-05
JP2020531539A5 JP2020531539A5 (https=) 2021-09-30

Family

ID=63643018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511450A Withdrawn JP2020531539A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用
JP2020511441A Withdrawn JP2020531537A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020511441A Withdrawn JP2020531537A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Country Status (5)

Country Link
US (3) US20200239564A1 (https=)
EP (2) EP3710476A1 (https=)
JP (2) JP2020531539A (https=)
TW (2) TW201919695A (https=)
WO (2) WO2019038737A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021517141A (ja) * 2018-03-09 2021-07-15 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 心血管疾患のための組み合わせ治療

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CN113491820A (zh) * 2021-07-30 2021-10-12 复旦大学附属中山医院 涂层Canakinumab的药物球囊的制备及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021517141A (ja) * 2018-03-09 2021-07-15 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 心血管疾患のための組み合わせ治療

Also Published As

Publication number Publication date
TW201919696A (zh) 2019-06-01
WO2019038737A1 (en) 2019-02-28
EP3710476A1 (en) 2020-09-23
WO2019038740A1 (en) 2019-02-28
JP2020531537A (ja) 2020-11-05
EP3710475A1 (en) 2020-09-23
US20200239564A1 (en) 2020-07-30
TW201919695A (zh) 2019-06-01
US20200199220A1 (en) 2020-06-25
US20240043525A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
De Luca et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study
Rose et al. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents
Gailani et al. Targeting factor XI and factor XIa to prevent thrombosis
Paquette et al. Cardiovascular disease, inflammation, and periodontal infection.
Tousoulis et al. Pathophysiology of atherosclerosis: the role of inflammation
JP2024109575A (ja) 対象の心血管イベントのリスクを低減する方法
Asanuma et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors.
JP2022554020A (ja) 心房細動および／または心房粗動を患う対象における心血管イベントのリスクを低減する方法
US20240043525A1 (en) Use of canakinumab
US20220187313A1 (en) Diagnosis or Prognosis of Postsurgical Adverse Events
Park et al. Association of acroosteolysis with enhanced osteoclastogenesis and higher blood levels of vascular endothelial growth factor in systemic sclerosis
TW201315482A (zh) ＩＬ－１β結合抗體之用途
Rizzo et al. Prediction of cardio-and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol
Tan et al. Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction
Targońska-Stępniak et al. Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis
Kölmel et al. Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension
Frączek et al. Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study
Liu et al. Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina
Wang et al. S100a9 lactylation triggers neutrophil trafficking and cardiac inflammation in myocardial ischemia/reperfusion injury
JP2007523837A (ja) Ｃ反応性タンパク質のレベルを低減するための方法
Molino-Lova et al. High sensitivity C-reactive protein predicts the development of new carotid artery plaques in older persons
Onuorah et al. Management of cardiovascular disease in the elderly
Xia et al. Asymmetric dimethylarginine predicts left atrial appendage thrombus in patients with non-valvular atrial fibrillation
JP7713983B2 (ja) カナキヌマブの使用
Andersen et al. Pulmonary vascular dysfunction in systemic sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210818

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20211001